See more : Belships ASA (NS6.F) Income Statement Analysis – Financial Results
Complete financial analysis of Cibus, Inc. (CBUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cibus, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tuscan Holdings Corp. II (THCAW) Income Statement Analysis – Financial Results
- Manitex International, Inc. (MNTX) Income Statement Analysis – Financial Results
- Woori Technology, Inc. (032820.KQ) Income Statement Analysis – Financial Results
- Luzhou Xinglu Water (Group) Co., Ltd. (2281.HK) Income Statement Analysis – Financial Results
- FaZe Holdings Inc. (FAZE) Income Statement Analysis – Financial Results
Cibus, Inc. (CBUS)
About Cibus, Inc.
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.82M | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 395.00K | 1.53M | 28.56M | 35.13M | 9.28M | 1.08M | 551.00K | 200.00K | 751.00K |
| Gross Profit | 1.42M | -1.38M | -2.57M | -11.28M | -1.98M | -845.00K | -43.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 78.26% | -877.07% | -9.89% | -47.28% | -27.19% | -358.05% | -8.46% | 49.87% | 40.96% |
| Research & Development | 42.37M | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.91M | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 249.02M | 5.57M | 19.00K | -126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 320.31M | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 320.70M | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 527.00K | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.89M | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 4.69M | 1.53M | 2.34M | 1.87M | 1.61M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -314.59M | -15.21M | -25.43M | -41.53M | -36.52M | -25.56M | -25.43M | -11.74M | -5.48M |
| EBITDA Ratio | -17,313.43% | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,810.59% | -4,968.11% | -2,948.37% | -445.52% |
| Operating Income | -318.88M | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -17,549.97% | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | -18.76M | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -337.64M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -18,582.44% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -4.00K | -1.45M | -114.00K | 1.56M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Net Income | -267.63M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -14,729.06% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| EPS Diluted | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| Weighted Avg Shares Out | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
| Weighted Avg Shares Out (Dil) | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
Cibus and Biographica Announce Collaboration Using Artificial Intelligence (AI) to Advance Disease Resistance in Canola and Oilseed Rape
Cibus and Biographica to collaborate on identifying gene editing targets for Cibus' disease resistance trait development
Cibus to Participate in the 13th Annual Roth Technology Conference
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and...
Cibus, Inc. (CBUS) Q3 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Carlo Broos - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants...
Cibus (CBUS) Q3 Earnings and Revenues Top Estimates
Cibus (CBUS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.90 per share. This compares to loss of $1.59 per share a year ago.
Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2024
Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development
Cibus Confirms its Herbicide Tolerance (HT2) Trait Shows Increased Tolerance to a Novel Herbicide for Weed Control in Canola
The greenhouse results represent an important success milestone in the development of its second-generation of HT2 edited Canola
Cibus to Report Third Quarter 2024 Financial Results on November 7, 2024 After the Market Close and Host Conference Call
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results...
Cibus Inc. Announces Realigned Organization to Advance its Commercial Opportunities
Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20% Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20%
Cibus Technology to be Featured on InnovAction Stage at the Euroseeds2024 Congress
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, has been named a finalist for the Euroseeds2024 InnovActor Award and will...
Cibus to Participate in the Food+ Forum during the 79th Session of the United Nations General Assembly
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, today announced that Peter Beetham, Co-Founder, President and Chief Operating Officer, will...
Source: https://incomestatements.info
Category: Stock Reports